[关键词]
[摘要]
增生性玻璃体视网膜病变(proliferative vitreoretinopathy，PVR)描述孔源性视网膜脱离(rhegmatogenous retinal detachment， RRD)等疾病后玻璃体和/或视网膜表面特异细胞增殖形成纤维膜继而收缩、牵拉引起相关疾病的过程。玻璃体切割手术是目前临床治疗PVR的标准方法。基于对各种细胞和生长因子在PVR致病过程中作用的逐渐了解，涌现出很多新兴的药物治疗方法，主要包括抗炎药物、抗肿瘤药物和抗生长因子药物等。
[Key word]
[Abstract]
Proliferative vitreoretinopathy(PVR)is a disease process that follows the proliferation of ectopic cell sheets in the vitreous and/or periretinal area, causing periretinal membrane formation, shrink and traction, in patients with rhegmatogenous retinal detachments. Pars plana vitrectomy is the standard treatment currently. There are many new drug therapies according to the functions of cytokines and growth factors in PVR, including anti-inflammatories, antineoplastic agents, antigrowth factors, and so on.
[中图分类号]
[基金项目]
